26 Aug 2019

RA MEDICAL SYSTEMS RECEIVES NYSE NOTICE RELATED TO DELAY IN FORM 10-Q FILING

           Ra Medical Systems, Inc., a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, has announced that it received a notice from the NYSE indicating that Ra Medical is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria

0
26 Aug 2019

BACKLOG OF VA HEALTH RECORD DIGITIZATION WOULD STACK 5 MILES HIGH

Despite the Veterans Health Administration reporting in July that they have transferred 23.5 million health records, covering some 78 billion data points, from the VA EHR to a shared data center with the DOD, if every single one of the paper documents that still need to be digitized at VA

0
12 Jul 2019

PAYER ANALYSIS: ‘CADILLAC TAX’ ON HIGH-COST HEALTH PLANS COULD AFFECT 1 IN 5 EMPLOYERS IN 2022

[/infobox]   A new KFF analysis estimates that the Affordable Care Act’s tax on high-cost health plans would affect one in five (21 percent) employers offering health benefits when it takes effect in 2022 unless employers change their health plans. An even larger share (31 percent) could be affected when workers’ voluntary

0
26 Jun 2019

CHARING CROSS 2019: MEDTRONIC EXPANDS ON KEY AORTIC SOLUTIONS FOR CHALLENGING ANATOMIES

  Medtronic plc released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant II/IIs stent graft system in combination with Heli-FX EndoAnchor implants and for the Valiant Navion thoracic stent graft system for thoracic endovascular repair (TEVAR). The data, which was presented at the Charing Cross

0
26 Jun 2019

ABBVIE ACQUIRING ALLERGAN AS HEDGE AGAINST EXPIRATION OF HUMIRA PATENT

As a hedge against the 2023 expiration of its U.S. patents that protect its blockbuster drug, Humira, AbbVie Inc. will acquire Dublin, Ireland-based Allergan for $63 billion in cash and stock.     Humira sales account for more than 60 percent of AbbVie’s revenue, but biosimilar drugs approved in Europe

0
25 Jun 2019

FUZZY MATH: Sanders’ Claim That Cost Barriers To HealthCare Kill 30,000 A Year IS only half true  

    TWEET “30,000 Americans a year die waiting for health care because of the cost.” –Sen. Bernie Sanders (I-Vt.), in a tweet June 20 By Shefali Luthra “Medicare for All” — or single-payer health care — is a flagship issue for Democratic presidential candidate and Vermont Sen. Bernie Sanders. So

0
25 Jun 2019

RATIONAL SUICIDE: Seniors want to call it quits on own schedule

(Caitlin Hillyard/KHN) By Melissa Bailey Ten residents slipped away from their retirement community one Sunday afternoon for a covert meeting in a grocery store cafe. They aimed to answer a taboo question: When they feel they have lived long enough, how can they carry out their own swift and peaceful

0
19 Jun 2019

VSA, PRACTICE MANAGEMENT FIRM, OBSERVES 17TH YEAR

  Vein Centers of America (VSA) is celebrating its 17th anniversary by offering a complimentary phone consultation with President and CEO David Schmiege.              in vein-specific practice management, marketing and revenue cycle management initiatives nationwide. “We have the experience, flexibility, structure and size to implement results quickly and to create the culture

0
12 Jun 2019

VICI VENOUS STENT: FDA OKs VICI Venous Stent to treat Iliofemoral obstructive disease

    The U.S Food and Drug Administration has approved Boston Scientific’s VICI Venous Stent System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies.

0
12 Jun 2019

VECLOSE EXTENSION STUDY: Five-year outcomes prove durability, safety, efficacy of VenaSeal Closure System

    By Larry Storer Five-year results from the 2019 VeClose Extension Study of the Medtronic VenaSeal Closure System demonstrate that the treatment modality is consistent, durable and safe for permanently closing veins in patients with venous reflux disease. When compared with Medtronic Radiofrequency Ablation, VenaSeal continued to show “non-inferiority”

0